Optinose Targets Broad Market with FDA-Approved Sinusitis Treatment XHANCE
YARDLEY, PA — Pharmaceutical company Optinose has outlined an ambitious commercial strategy following the FDA’s recent approval of XHANCE (fluticasone propionate) for a new indication in treating chronic rhinosinusitis without …
Optinose Targets Broad Market with FDA-Approved Sinusitis Treatment XHANCE Read More